Esterase-sensitive cleavable histone deacetylase inhibitor-coupled hyaluronic acid nanoparticles for boosting anticancer activities against lung adenocarcinoma

Lee, Song Yi; Hong, Eock Kee; Jeong, Jae Young; Cho, Jaewon; Seo, Jeong‐Meen; Ko, Hyun‐Jeong; Cho, Hyun‐Jong

doi:10.1039/c9bm00895k

Cited by 40 publications

(22 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Encapsulation of MS-275 with silver nanoparticles maintains the drug's mechanism of action in the lung cancer cell line model. This work explains that this combination of silver nanoparticles and HDACi induces apoptosis, accompanied by increased expression of reactive oxygen species and induction of DNA fragmentation [139] .…”

Section: Nanoparticle Mediated Delivery Of Hdac Inhibitorsmentioning

confidence: 71%

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases

Shanmugam

Rakshit

Sarkar

2022

Translational Oncology

View full text Add to dashboard Cite

Highlights HDACs are dysregulated in various malignancies and in some inflammatory lung diseases. HDAC inhibitors are emerging as a successful epigenetic therapy by exploiting pathophysiology of tumor microenvironment. HDAC inhibitors can activate multiple antitumor pathway which results in the destruction of transformed cells. Nanocarrier-based HDACi delivery is a huge step forward in improving the targeted delivery of HDAC inhibitors.

show abstract

Section: Nanoparticle Mediated Delivery Of Hdac Inhibitorsmentioning

confidence: 71%

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases

Shanmugam

Rakshit

Sarkar

2022

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…Given the heterogeneity of various HDACs and their role in regulating genes involved in different cellular pathways, development of more selective HDACi, preferably HDAC class I inhibitors, with potent anti-tumor activity and more favorable side effect profile is desirable. Recent development of technologies to utilize nanocarriers, such as polymeric nanoparticles, PEG-coated nanoparticles, colloid carrier systems, PLGA nanoparticles, and albumin microspheres, are being investigated in clinical studies to deliver HDACi with enhanced solubility, tumor specificity and less toxicity ( Enriquez et al, 2013 ; Martin et al, 2013 ; Goswami et al, 2018 ; Bertrand et al, 2019 ; Lee et al, 2019 ). Moreover, the optimum timing of administration of HDACi with other treatments remains unknown.…”

Section: Challenges and Future Directionsmentioning

confidence: 99%

Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?

Mamdani

Jalal

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Epigenetic modulation, including acetylation, methylation, phosphorylation, and ubiquitination, plays a pivotal role in regulation of gene expression. Histone acetylation—a balance between the activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs)—is one of the key epigenetic events. Our understanding of the role of HDACs in cancer is evolving. A number of HDAC isoenzymes are overexpressed in a variety of malignancies. Aberrant histone acetylation is associated with dysregulation of tumor suppressor genes leading to development of several solid tumors and hematologic malignancies. Pre-clinical studies have demonstrated that HDAC-1 gene expression is associated with lung cancer progression. Histone hypoacetylation is associated with more aggressive phenotype in adenocarcinoma of the lung. HDAC inhibitors (HDACi) have pleiotropic cellular effects and induce the expression of pro-apoptotic genes/proteins, cause cellular differentiation and/or cell cycle arrest, inhibit angiogenesis, and inhibit transition to a mesenchymal phenotype. Consequently, treatment with HDACi has shown anti-proliferative activity in non-small cell lung cancer (NSCLC) cell lines. Despite promising results in pre-clinical studies, HDACi have shown only modest single agent activity in lung cancer clinical trials. HDAC activation has been implicated as one of the mechanisms causing resistance to chemotherapy, molecularly targeted therapy, and immune checkpoint inhibition. Therefore, there is a growing interest in combining HDACi with these agents to enhance their efficacy or reverse resistance. In this paper, we review the available preclinical and clinical evidence for the use of HDACi in NSCLC. We also review the challenges precluding widespread clinical utility of HDACi as a cancer therapy and future directions.

show abstract

“…Epigenetic modulators are another category of molecules that might benefit from the development of NP-based delivery strategies. For example, histone deacetylase inhibitors (HDACi) have been implemented within tumor-targeting particles showing significant inhibitory effects on tumor growth ( Bertrand et al, 2019 ; Lee S. Y. et al, 2019 ). Studies evaluating the effects on the TIME of targeted HDACi therapy should be encouraged after the effects observed by selective HDACi in an NP-free treatment ( McCaw et al, 2019 ).…”

Section: Nanotechnologies For Therapeutic Deliverymentioning

confidence: 99%

Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment

Giustarini

Pavesi

Adriani

2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Nanotechnologies are rapidly increasing their role in immuno-oncology in line with the need for novel therapeutic strategies to treat patients unresponsive to chemotherapies and immunotherapies. The tumor immune microenvironment (TIME) has emerged as critical for tumor classification and patient stratification to design better treatments. Notably, the tumor infiltration of effector T cells plays a crucial role in antitumor responses and has been identified as the primary parameter to define hot, immunosuppressed, excluded, and cold tumors. Organic and inorganic nanoparticles (NPs) have been applied as carriers of new targeted therapies to turn cold or altered (i.e., immunosuppressed or excluded) tumors into more therapeutically responsive hot tumors. This mini-review discusses the significant advances in NP-based approaches to turn immunologically cold tumors into hot ones.

show abstract

Esterase-sensitive cleavable histone deacetylase inhibitor-coupled hyaluronic acid nanoparticles for boosting anticancer activities against lung adenocarcinoma

Abstract: 4-Phenylbutyric acid (PBA)-installed hyaluronic acid (HA)-based nanoparticles (NPs) were developed for amplifying the anticancer potential of curcumin (CUR) for lung cancer therapy.

Cited by 40 publications

References 42 publications

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases

Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?

Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment

Contact Info

Product

Resources

About